Bcl-2 and apoptosis in chronic lymphocytic leukemia

Current Treatment Options in Oncology

Volumn 4, Issue 3, 2003, Pages 211-218

  Schimmer, Aaron D ^a   Munk Pedersen, Irene ^b   Minden, Mark D ^b   Reed, John C ^b  

^a BURNHAM INSTITUTE   (United States)

^b NONE

Author keywords

Antisense Oligonucleotide; Chronic Leukemia; Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia Sample; Primary Chronic Lymphocytic Leukemia

Indexed keywords

PROTEIN BCL 2;

APOPTOSIS; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; METABOLISM; PATHOLOGY; REVIEW;

APOPTOSIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0141449250     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-003-0022-y     Document Type: Article

References (28)

1. Schimmer A, Hedley DW, Penn LZ, et al.: Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood 2001, 98:3541–3553. DOI: 10.1182/blood.V98.13.3541
2. Tsujimoto Y, Shimizu S: Bcl-2 family: live or death switch. FEBS Lett 2000, 466:6–10. DOI: 10.1016/S0014-5793(99)01761-5
3. Kitada S, Andersen J, Akar S, et al.: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998, 91:3379–3389.
4. Basanez G, Nechusht A, Drozhinin O, et al.: Bax, but not Bcl-xl, decreases the lifetime of planar phospholipid bilayer membranes at subnanomolar concentrations. Proc Natl Acad Sci U S A 1999, 96:5492–5497. DOI: 10.1073/pnas.96.10.5492
5. Tsukada N, Burger JA, Zvaifler NJ, et al.: Distinctive features of “nurse-like” cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002, 99:1030–1037. DOI: 10.1182/blood.V99.3.1030
6. Faderl S, Keating MJ, Do KA, et al.: Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002, 16:1045–1052. This paper involves a large trial demonstrating the prognostic importance of Bcl-2 in CLL. DOI: 10.1038/sj.leu.2402540
7. Robertson LE, Plunkett W, McConnell K, et al.: Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996, 10:456–459.
8. Molica S, Dattilo A, Giulino C, et al.: Increased Bcl-2/ bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease. Haematologica 1998, 83:1122–1124.
9. Nakayama K, Negishi I, Kuika K, et al.: Targeted disruption of Bcl-2— in mice: occurrence of gray hair, polycystic disease, and lymphocytopenia. Proc Natl Acad Sci U S A 1994, 91:3700–3704. DOI: 10.1073/pnas.91.9.3700
10. Park JR, Bernstein ID, Hockenbery DM: Primitive human haematopoietic precursors express Bcl-x but not Bcl-2. Blood 1995, 86:868–876.
11. Pepper C, Hooper K, Thomas A, et al.: Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells. Leuk Lymphoma 2001, 42:491–498.
12. Jansen B, Wacheck V, Heere-Ress E, et al.: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000, 356:1728–1733. This paper discusses a trial demonstrating the safety of Bcl-2 antisense therapy. DOI: 10.1016/S0140-6736(00)03207-4
13. Rudin CM, Otterson GA, Mauer AM, et al.: A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002, 13:539–545. DOI: 10.1093/annonc/mdf124
14. Greco FA, Stroup SL, Gray JR, Hainsworth JD: Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Clin Oncol 1996, 14:1642–1648.
15. Chi KN, Gleave ME, Klasa R, et al.: A phase I dosefinding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormonerefractory prostate cancer. Clin Cancer Res 2001, 7:3920–3927.
16. Waters JS, Webb A, Cunningham D, et al.: Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma. J Clin Oncol 2000, 18:1812–1823.
17. Derenne S, Monia B, Dean NM, et al.: Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells. Blood 2002, 100:194–199. DOI: 10.1182/blood.V100.1.194
18. Wang JL, Zhang ZJ, Choksi S, et al.: Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res 2000, 60:1498–1502.
19. Wang JL, Liu D, Zhang ZJ, et al.: Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 2000, 97:7124–7129. DOI: 10.1073/pnas.97.13.7124
20. Hu G, Khodadoust M, Konopleva M, et al.: Induction of apoptosis in lymphoid cell lines and primary CLL by HA14-1, a cell permeable organic small molecule that binds to the BH1 to BH3 surface pocket of bcl-2 protein. Am Assoc Cancer Res Abstracts 2002. http://www.aacr.org.
21. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031–1037. DOI: 10.1056/NEJM200104053441401
22. Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038–1042. DOI: 10.1056/NEJM200104053441402
23. O’Gorman DM, McKenna SL, McGahon AJ, et al.: Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of P13-kinase survival signals. Leukemia 2000, 14:602–611. DOI: 10.1038/sj.leu.2401726
24. Koh H, Lee KH, Kim D, et al.: Inhibition of Akt and its anti-apoptotic activities by tumor necrosis factorinduced PRK2 cleavage. J Biol Chem 2000, 275:34451–34458. DOI: 10.1074/jbc.M001753200
25. Ashkenazi A, Pai RC, Fong S, et al.: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155–162. DOI: 10.1172/JCI6926
26. Pedersen IM, Kitada S, Schimmer A, et al.: The triterpenoid CDDO induces apoptosis in refractory CLL Bcells. Blood 2002, 100:2965–2972. DOI: 10.1182/blood-2002-04-1174
27. Ito Y, Pandey P, Place A, et al.: The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ 2000, 11:261–267.
28. Konopleva M, Tsao T, Ruvolo P, et al.: Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 2002, 99:326–335. DOI: 10.1182/blood.V99.1.326